Opportunity Information: Apply for RFA AI 16 024
Apply for RFA AI 16 024
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856,.
- This funding opportunity was created on Apr 07, 2016 and posted on Apr 07, 2016.
- Applicants must submit their applications by Aug 03, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01)" (Funding Opportunity Number RFA-AI-16-024) is a discretionary NIH grant solicitation under the U.S. Department of Health and Human Services. It sits in the health research category and is associated with CFDA program numbers 93.855 and 93.856, which align with NIH infectious disease and allergy/immunology-related research activities. The central aim of the announcement is to push forward the early discovery and selection of anti-HIV small molecules that could realistically be turned into sustained-release products, meaning formulations designed to maintain therapeutic drug levels for extended periods without frequent dosing.
The scientific focus is on identifying either (1) existing anti-HIV molecules that are already known but may be underutilized or not yet optimized for long-acting delivery, or (2) brand-new small molecules that are highly potent and highly selective against HIV. In either case, the emphasis is not simply on finding any active compound, but on finding candidates that have a credible path toward sustained-release development. The FOA is explicitly oriented toward products that could support dosing intervals ranging from about once weekly to once every three months or even longer. In practical terms, this steers applicants toward compounds with properties that can support long duration of action, such as strong antiviral potency (so lower amounts of drug are needed), favorable stability, and a pharmacologic profile that could be compatible with long-acting formulations.
The award mechanism is an R01 research project grant, which generally supports hypothesis-driven or objective-driven biomedical research projects and is commonly used for substantial, multi-aim research plans. The announcement invites applications from either single institutions or consortia of institutions, signaling that both standalone laboratories and multi-partner collaborations are acceptable. That consortium language is important because discovering and triaging long-acting candidates often spans multiple skill sets, for example medicinal chemistry, virology, pharmacology, and formulation or drug delivery science. While the FOA text provided does not list specific required tasks, the stated purpose strongly implies work such as screening and lead identification, potency and selectivity testing, and early assessments of whether a candidate can plausibly fit a sustained-release product profile.
Eligibility is broad and includes most major organizational types that typically participate in NIH research funding. Eligible applicants include federal recognized tribal governments and tribal organizations, state and local governments, public and private institutions of higher education, nonprofits with or without 501(c)(3) status (excluding higher education institutions in that subcategory), for-profit organizations (other than small businesses), and small businesses, as well as other entities as clarified in the full FOA. This wide eligibility suggests NIH was trying to attract a diverse set of applicants across academia, industry, nonprofit research groups, and government-affiliated entities, which fits the translational nature of long-acting HIV drug development.
Administratively, the opportunity was posted on April 7, 2016, with the same date listed as the creation date, and it had an original and current closing date of August 3, 2016. The agency is listed as HHS-NIH11, indicating a component within NIH under HHS. The source excerpt does not provide an award ceiling or the expected number of awards, leaving those fields blank, so applicants would have needed to consult the full FOA for budget expectations, project period guidance, and any institute-specific funding plan details.
In summary, RFA-AI-16-024 was designed to accelerate the pipeline of small-molecule anti-HIV candidates that are not only effective but also suitable for transformation into long-acting, sustained-release therapies or preventives. The key theme is enabling less frequent dosing, from weekly to quarterly or longer, by supporting research that discovers or identifies potent, selective molecules with characteristics compatible with sustained-release product development.
FAQs: Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01) (RFA-AI-16-024)
What is the title of this funding opportunity?
The funding opportunity is titled "Identification of Small Molecules for Sustained-Release Anti-HIV Products (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AI-16-024.
Which agency is offering this opportunity?
This is an NIH funding opportunity under the U.S. Department of Health and Human Services (HHS). The agency listing in the provided information is HHS-NIH11.
What type of grant mechanism is being used?
The award mechanism is an NIH R01 research project grant.
What is the main goal of this FOA?
The main goal is to advance early discovery and selection of anti-HIV small molecules that could realistically be developed into sustained-release (long-acting) products designed to maintain therapeutic drug levels for extended periods without frequent dosing.
What does "sustained-release" mean in the context of this opportunity?
In this context, sustained-release refers to formulations intended to maintain therapeutic drug levels over extended time periods, reducing the need for frequent dosing.
What dosing intervals is this FOA aiming to support?
The FOA is oriented toward products that could support dosing intervals ranging from about once weekly to once every three months or even longer.
What kinds of small molecules are of interest?
The FOA focuses on two categories: (1) existing anti-HIV molecules that are already known but may be underutilized or not yet optimized for long-acting delivery, and (2) brand-new small molecules that are highly potent and highly selective against HIV.
Is the FOA focused on any anti-HIV compound, or specifically on long-acting candidates?
The emphasis is specifically on identifying candidates that have a credible path toward sustained-release development, not merely any compound with anti-HIV activity.
What scientific characteristics are implied to be important for long-acting development?
Based on the description, the FOA steers applicants toward compounds with properties supportive of long duration of action, such as strong antiviral potency (so lower amounts of drug are needed), favorable stability, and a pharmacologic profile compatible with long-acting formulations.
What research activities are implied by the purpose of the FOA?
While specific required tasks are not listed in the excerpt, the stated purpose strongly implies activities such as screening and lead identification, potency and selectivity testing, and early assessments of whether a candidate plausibly fits a sustained-release product profile.
Is this opportunity suitable for single institutions or does it require a consortium?
The announcement invites applications from either single institutions or consortia of institutions, meaning both standalone projects and multi-partner collaborations are acceptable.
Why does the FOA mention consortia as an option?
The consortium language signals that multi-disciplinary collaborations are appropriate, since discovering and triaging long-acting candidates often spans multiple skill sets (for example medicinal chemistry, virology, pharmacology, and formulation or drug delivery science).
What is the research category for this opportunity?
The opportunity sits in the health research category.
Which CFDA program numbers are associated with this FOA?
The associated CFDA program numbers are 93.855 and 93.856.
What do the listed CFDA numbers relate to?
Based on the provided information, these CFDA numbers align with NIH infectious disease and allergy/immunology-related research activities.
Who is eligible to apply?
Eligibility is broad and includes: federally recognized tribal governments and tribal organizations; state and local governments; public and private institutions of higher education; nonprofits with or without 501(c)(3) status (excluding higher education institutions in that subcategory); for-profit organizations (other than small businesses); small businesses; and other entities as clarified in the full FOA.
Are for-profit entities eligible?
Yes. The eligibility list includes for-profit organizations (other than small businesses) as well as small businesses.
Are small businesses eligible?
Yes, small businesses are included in the eligibility list.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments and tribal organizations are explicitly listed as eligible applicants.
Are state and local governments eligible?
Yes. State and local governments are included in the eligibility list.
Are nonprofits eligible?
Yes. Nonprofits with or without 501(c)(3) status are included (with the note that the "nonprofits without 501(c)(3)" subcategory excludes higher education institutions).
When was this funding opportunity posted?
It was posted on April 7, 2016 (the same date is listed as the creation date).
What was the application closing date?
The original and current closing date listed is August 3, 2016.
Is the award ceiling or number of awards specified in the provided information?
No. The excerpt leaves the award ceiling and the expected number of awards blank, indicating that applicants would have needed to consult the full FOA for budget expectations and funding details.
Does the provided information include budget expectations or the project period?
No. The excerpt does not provide budget expectations, project period guidance, or institute-specific funding plan details.
What is the overall takeaway of RFA-AI-16-024?
RFA-AI-16-024 was designed to accelerate the pipeline of small-molecule anti-HIV candidates that are not only effective but also suitable for transformation into long-acting, sustained-release therapies or preventives, with a key theme of enabling less frequent dosing (weekly to quarterly or longer).
Browse more opportunities from the same category: Health
Next opportunity: BLM OR/WA - Siuslaw Watershed Restoration, Eugene District
Previous opportunity: Cooperative Ecosystem Studies Unit, Rocky Mountain CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 16 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 16 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing HIV Therapeutic Vaccine Science (U01) Apply for RFA AI 16 019 Funding Number: RFA AI 16 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Human Tissue Models for Infectious Diseases (U19) Apply for RFA AI 16 022 Funding Number: RFA AI 16 022 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Noise-Induced Cochlear Synaptopathy: Basic Studies Informing Potential Therapies (R01) Apply for PAR 16 170 Funding Number: PAR 16 170 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| Innovation for HIV Vaccine Discovery (R01) Apply for PAR 16 171 Funding Number: PAR 16 171 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: IDeA (Institutional Development Award) Core Optimization (Admin Supp) Apply for PA 16 172 Funding Number: PA 16 172 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Research Partnerships for Scaling Up Mental Health Interventions in Low-and Middle-Income Countries (U19) Apply for PAR 16 174 Funding Number: PAR 16 174 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Apply for CDC RFA TS15 150102CONT16 Funding Number: CDC RFA TS15 150102CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Resiliency in Communities After Stress and Trauma (Short Title: ReCAST Program) Apply for SM 16 012 Funding Number: SM 16 012 Agency: HHS-SAMHS Category: Health Funding Amount: $1,000,000 |
| ResPECT Data Anaysis Apply for EP IDS 16 002 Funding Number: EP IDS 16 002 Agency: HHS-OS-ASPR Category: Health Funding Amount: $386,500 |
| Limited Competition: Tissue Chips for Rare Diseases (Admin Supp) Apply for PA 16 173 Funding Number: PA 16 173 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
| Limited Competition: Tissue Chips and Missing Organs (Admin Supp) Apply for PA 16 178 Funding Number: PA 16 178 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| Minority AIDS Initiative Continuum of Care Pilot (MAI-CoC) Syringe Services Programs (SSPs) (Short Title: MAI-CoC: SSP) Apply for SP 16 008 Funding Number: SP 16 008 Agency: HHS-SAMHS Category: Health Funding Amount: $82,500 |
| TRANSFORM/WASH Apply for RFA 663 16 000007 Funding Number: RFA 663 16 000007 Agency: USAID-ETH Category: Health Funding Amount: $24,000,000 |
| Tribal Management Grant Program Apply for HHS 2016 IHS TMD 0001 Funding Number: HHS 2016 IHS TMD 0001 Agency: HHS-IHS Category: Health Funding Amount: $100,000 |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42) Apply for PA 16 181 Funding Number: PA 16 181 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R43/R44) Apply for PA 16 180 Funding Number: PA 16 180 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18) Apply for PAR 16 179 Funding Number: PAR 16 179 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R41/R42) Apply for PA 16 182 Funding Number: PA 16 182 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Products to Support Applied Research Towards Zero Suicide Healthcare Systems (R43/R44) Apply for PAR 16 185 Funding Number: PAR 16 185 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R43/R44) Apply for PA 16 184 Funding Number: PA 16 184 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.